Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872534 · ClinicalTrials.gov registry record · Phase 1
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
A Phase 1 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
NCT00872534 is a Phase 1 study that has completed, run by PLx Pharma. The registered enrollment target is 204 participants.
The verdict
NCT00872534, a Phase 1 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
Study Summary
To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.
Interventions
- DRUG acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00872534
The ClinicalTrials.gov registry entry for NCT00872534 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which acetylsalicylic acid is the first listed.
NCT00872534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00872534 about?
NCT00872534 is a clinical study titled "Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers". To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.
What is the current status of trial NCT00872534?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00872534?
The interventions under investigation include: acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT00872534?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.